943TiP PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
| Autor: | Saba, N., Youssoufian, H., Cohen, E., Singh, J., Makris, L., Perdomini, M., MacIntyre, S., Denker, A. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S592-S592 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|